Cell Culture Media for Vaccine Market to Surpass US$ 2.22 Billion by 2026

Global Cell Culture Media for Vaccine Market, by Media Type (Bovine Derived, Porcine Derived, and Animal Free/Serum Free Cell Culture), by Application (Human Vaccine and Animal Vaccine), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1,235.5 million in 2017 and is projected to exhibit a CAGR of 7.7% over the forecast period (2018 – 2026).

Key players in the market are focused on research and development in order to develop novel research grade products to cater the need of researchers. For instance, in November 2017, Proliant Biologicals launched New Zealand manufactured Reagent Grade (Fatty Acid-Free) BSA. The product is derived from New Zealand-origin healthy animals. Moreover, increasing number of government initiatives to prevent certain diseases and epidemic caused due to vaccine-preventable diseases is expected to boost the market growth. Furthermore, increasing number of countries are conducting national immunization programs to provide vaccination and promote awareness regarding advantages of vaccination to fight fatal diseases with natural immunity among adults as well as children. For instance, in 2015, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) partnered with the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to support the advanced development of new and better influenza vaccines as a part of inter-agency government effort in the U.S.

Browse 33 Market Data Tables and 27 Figures spread through 197 Pages and in-depth TOC on ‘Cell Culture Media for Vaccine Market’- Global Forecast to 2026, by Media Type (Bovine Derived, Porcine Derived, and Animal Free/Serum Free Cell Culture), by Application (Human Vaccine and Animal Vaccine), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the cell culture media for market, click the link below:

https://www.coherentmarketinsights.com/market-insight/cell-culture-media-for-vaccine-market-2608

Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, In November 2015, Merck KGaA, which is a parent company of Merck Millipore, acquired the U.S.-based life science company, Sigma-Aldrich Corporation, at US$ 17 Bn through its U.S. subsidiary EMD Millipore. A combined entity known as MilliporeSigma was formed in the U.S. market and this acquisition made Merck Millipore one of the top three players in the global life science market.

Key Takeaways of the Global Cell Culture Media for Vaccine Market:

The global cell culture media for vaccine market is expected to exhibit a CAGR of 7.7 % over the forecast period, owing to increasing prevalence of infectious diseases, increasing number of government initiatives, and increasing availability of innovative bovine blood plasma derivatives. For instance, in August 2017, Animal Free Research UK and the 3Rs-Centre Utrecht Life Sciences launched the Fetal Calf Serum (FCS)-free database. The database enables researchers to identify serum-free media for specific cell types, thereby contributing to the adoption of animal free media for research.
Among application type, human vaccine segment is estimated to hold a dominant position in the cell culture media for vaccine market in 2018, owing to higher usage of bovine derived serum products in biotechnology research, vaccine production, cloning, and in vitro fertilization
Among media type, bovine derived is estimated to hold a dominant position in the cell culture media for vaccine market in 2018, as manufacturing of viral vaccines require fetal bovine serum or other sera as a source of nutrition or growth media for the virus growth
Key players operating in the global cell culture media for vaccine market include, HiMedia Laboratories, Thermo Fisher Scientific Inc., Merck KGaA, General Electric Company, Sartorius AG, Proliant, Inc., Bovogen Biologicals Pty. Ltd., Rocky Mountain Biologicals, Valley Biomedical, Moregate BioTech, Atlanta Biologicals, Creative-Biolabs, Life Technologies (India) Pvt Ltd., Axil Scientific Pte Ltd., Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Sisco Research Laboratories Pvt. Ltd., and Valneva SE